EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis

Pierre Gourdy iD, Riccardo C Bonadonna, Didac Mauricio iD, Dirk Müller-Wieland iD, Celine Mauquoi, Carine Vera, Mireille Bonnemaire, Nick Freemantle iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Pierre Gourdy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetology and Nutrition Department, Toulouse University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Insulin Glargine, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycated Hemoglobin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi (Paris, France).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) initiation according to diabetes duration (DD). Materials and Methods We analysed patient‐level data from 2381 insulin‐naïve individuals with type 2 diabetes (T2D), of whom 2349 (98.7%) were treated with Gla‐300 for 24 weeks. Of the 2381 participants, 1048 (44.0%) had a DD of less than 8 years and 1333 (56.0%) had a DD of 8 years or longer. We further analysed the subgroups of participants having a DD of less than 4 years ( N = 450), 4‐8 years ( N = 598), 8‐12 years ( N = 627) and 12 years or longer ( N = 706).

Results

Mean ± standard deviation age was 60.2 ± 9.0 years in participants with a DD less than 8 years and 64.2 ± 8.8 years in those with a DD of 8 years or longer. At 24 weeks of Gla‐300 therapy, HbA1c improved with a least‐squares (LS) mean change from baseline of −1.88% (95% confidence interval [CI], −1.95 to −1.80) and −1.71% (95% CI, −1.77 to −1.65), respectively, resulting in a LS mean difference between groups of 0.17% (95% CI, 0.07 to 0.26; P = .0005). In the subgroup analysis, LS mean HbA1c reduction from baseline to week 24 was highest in participants with a DD of less than 4 years and lowest in participants with a DD of 12 years or longer. Overall, incidences of symptomatic and severe hypoglycaemia were low, irrespective of DD, without body weight changes.

Conclusions

Gla‐300 was effective and safe in insulin‐naïve individuals with T2D, regardless of DD. Improvement in HbA1c was greater when Gla‐300 was initiated in participants with a DD of less than 4 years, although the difference between the groups was modest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin GlargineDiabetes Mellitus, Type 2Hypoglycemic AgentsGlycated HemoglobinHypoglycemiaHumansMaleMiddle AgedFemaleAgedTreatment OutcomeBlood GlucoseEuropeTime Factors

Stichwörter der Autor:innen

Gla‐300diabetes durationinsulin glargine 300 U/mLinsulin‐naïvetype 2 diabetes

Substanzen

Insulin GlargineHypoglycemic AgentsGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Endocrinology, Diabetology and Nutrition Department, Toulouse University Hospital, Toulouse, France.
  • Institute of Metabolic and Cardiovascular Diseases, UMR1297 INSERM/UPS, Toulouse University, Toulouse, France.
  • Azienda Ospedaliero-Universitaria di Parma, Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Department of Endocrinology and Nutrition, CIBERDEM, Hospital de la Santa Creu i Sant Pau Institut de Recerca, Barcelona, Spain.
  • Department of Medicine I, University Hospital Aachen, Aachen, Germany.
  • IDDI, Louvain-la-Neuve, Belgium.

ORCID-Profile: Pierre Gourdy, Didac Mauricio, Dirk Müller-Wieland, Nick Freemantle

Förderung

  • Sanofi (Paris, France)

Zitieren

APA

Gourdy, P., Bonadonna, R. C., Mauricio, D., Müller-Wieland, D., Mauquoi, C., Vera, C., Bonnemaire, M., & Freemantle, N. (2025). Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16008

Vancouver

Gourdy P, Bonadonna RC, Mauricio D, Müller-Wieland D, Mauquoi C, Vera C, et al. Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16008

BibTeX
@article{Gourdy2025,
  author = {Gourdy, Pierre and Bonadonna, Riccardo C and Mauricio, Didac and Müller-Wieland, Dirk and Mauquoi, Celine and Vera, Carine and Bonnemaire, Mireille and Freemantle, Nick},
  title = {Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16008}
}
Kostenlos starten →